ACTRN12624000877583招募中Unknown
Evaluation of Community Pharmacists Management of patients with Acute exacerbations of Atopic Dermatitis (6 months to 65 years), Impetigo (12 months and above), Mild-Plaque Psoriasis and Herpes Zoster (18 years and above): PATH-DERM
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 22,857
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 6 Months 至 o limit（—）
- 性别
- All
入选标准
- •Pharmacies and pharmacists recruited must meet the eligibility criteria (defined below) to participate in the study, reflecting the criteria set by the Authority under Section 10 Poisons and Therapeutic Good Act 1966 Clauses 170 and 171 of the Poisons and Therapeutic Goods Regulation 2208.
- •Community pharmacies
- •A community pharmacy in NSW or ACT must have a service room, consulting room, or area consistent with the following:
- •An ‘approved pharmacy’ means a pharmacy or class of pharmacies, approved in writing by the Chief Health Officer, which has a service room, consulting room, or area consistent with the following:
- •o the room or area is not to be used as a dispensary, storeroom, staff room or retail area,
- •o fully enclosed and provides adequate privacy (a divider or curtain in a dispensary, storeroom, staff room or retail area is not acceptable),
- •o has adequate lighting,
- •o is maintained at a comfortable ambient temperature,
- •o has a hand sanitisation facility,
- •o has ready access to a hand washing facility, and
- •o has sufficient floor area, clear of equipment and furniture, to accommodate the person receiving the consultation and an accompanying person, and to allow the pharmacist adequate space to manoeuvre.”
- •Pharmacies must have access to MedAdvisor to complete clinical record keeping for the purposes of the clinical trial assessment. The pharmacy must have at least one eligible pharmacist who is willing to provide their voluntary consent to participate, for the pharmacy to be eligible, and that there is always a pharmacist available to deliver the service during all opening hours of the pharmacy.
- •Pharmacists
- •The eligibility criteria for an approved pharmacist to participate in the study, which includes that the pharmacist must be:
- •Prior to service delivery, pharmacists will be prepared through an educational program. This program consists of the following training modules:
- •Australasian College of Pharmacy (ACP) modules on Impetigo, Atopic Dermatitis, Mild Plaque Psoriasis and Herpes Zoster; or
- •Pharmaceutical Society of Australia (PSA) module on dermatology conditions (Mild Plaque Psoriasis, Impetigo, Herpes Zoster and Atopic Dermatitis); and
- •Modules developed by the University of Newcastle for the clinical trial (Introduction, Clinical Practice Guidelines, Antimicrobial Resistance and Stewardship for Impetigo and Herpes Zoster, and Introduction to Prescribing).
- •Completing this educational program is expected to take between 8 and 10 hours in total.
- •A pharmacist is eligible to participate if they hold general registration as a pharmacist with the Australian Health Practitioner Regulation Agency (AHPRA). Pharmacists with provisional registration (intern pharmacists) and pharmacists with conditions on their registration are not eligible to participate in the trial.
- •The pharmacy must have at least one eligible pharmacist who is willing to provide their voluntary consent to participate, for the pharmacy to be eligible, and that there is always a pharmacist available to deliver the service during all opening hours of the pharmacy.
- •Patients will be opportunistically recruited in participating community pharmacy. Consecutive patients will be identified on presentation to the community pharmacy with symptoms suggestive one of the four skin conditions and either: presenting symptoms requesting advice or self-selecting a product for symptoms for the conditions in
排除标准
- •Individuals outside the age range for each condition.
研究者
相似试验
已完成
不适用
Evaluation of a community pharmacist-led minor ailments service in collaboration with general practitioners: a cluster randomised controlled trialCommon coldGastroesophageal refluxTension headacheCoughPrimary dysmenorrhoeaNon specific low back painOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonRespiratory - Other respiratory disorders / diseasesInfection - Other infectious diseasesReproductive Health and Childbirth - Menstruation and menopauseNeurological - Other neurological disordersMusculoskeletal - Other muscular and skeletal disordersMigraineACTRN12618000286246niversity of Technology Sydney894
尚未招募
Unknown
Evaluation of efficacy of the community pharmacy intervention to optimize serum potassium levels in patients with chronic kidney diseasechronic kidney diseaseJPRN-UMIN000049814ational Hospital Organization Mie Chuo Medical Center40
已完成
不适用
Assessment of community pharmacies' support for smoking cessation treatment in collaboration with medical institutionsSmoking cessationJPRN-UMIN000044380School of Pharmacy, Nihon University70
招募中
不适用
Increasing Community Pharmacy Involvement in the Prevention of Cardiovascular Disease ProjectACTRN12609000705280Monash450
已完成
不适用
Evaluation of the use of a patient questionnaire in measuring patient reported outcomes of medication reviewsadverse drug reactions (ADRs), side effects of drugs, medication adherence (MARS), beliefs about medicines necessity and concerns (BMQ), self efficacy (MUSE)NL-OMON28732Radboud university medical center, Radboud Institute for Health Sciences, IQ Healthcare, Nijmegen, The Netherlands200